Invited reviewmTOR inhibitors and diabetes
Introduction
The mammalian target of rapamycin (mTOR) inhibitors are drugs that are potent immunosuppressors used for prevention of acute rejection following solid-organ transplantation [1]. They have more recently been developed as antineoplastic targeted therapies in various cancers because of their inhibiting effects on signaling pathways involved in cell growth and metabolism [2], [3], [4], [5], [6], [7]. mTOR inhibitors have several metabolic adverse events including hyperlipidemia and hyperglycemia [8]. The rate of diabetes induced by mTOR inhibitors is high and patients receiving such treatment need careful follow-up of blood glucose levels. In this review, we will briefly mention the main indications of mTOR inhibitors, present the mTOR signaling system and the actions of mTOR on glucose metabolism, present the effects of mTOR inhibitors on glycemia, analyze the possible pathophysiological mechanisms responsible for the hyperglycemia induced by mTOR inhibitors and discuss the management of hyperglycemia induced by mTOR inhibitors.
Section snippets
Main indications of mTOR inhibitors
mTOR inhibitors were first used as anti-rejection agents for transplantation before being developed as targeted anti-cancer therapies [1]. Both sirolimus (i.e., rapamycin) and everolimus are used as anti-rejection treatment when everolimus and temsirolimus are used as targeted anti-cancer therapies. Everolimus is used for both indications but with lower doses for anti-rejection (1.5–3.0 mg/day) than for anti-cancer (5–10 mg/day) treatment.
mTOR inhibitors are agents that inhibit signaling in the
mTOR signaling
mTOR is a serine/threonine protein kinase, belonging to the PI3K-related kinase family, playing a key role in regulating cell growth as well as lipid and glucose metabolism. The protein mTOR is expressed throughout the body and is present in brain, cardiopulmonary system, gastrointestinal tract, immune system, skeletal system and the reproductive system [9]. mTOR exists in two distinct large multi-protein complexes: mTOR complex 1 (mTORC1) and complex 2 (mTORC2) [10], [11].
mTORC1 is composed of
mTOR and glucose metabolism
The effects of mTOR on glucose homeostasis are complex with some opposite results depending on the level of mTORC1 activity [11]. mTORC1 promotes insulin resistance in adipose tissue through the S6K1-mediated inhibition of insulin signaling, linked to the serine-phosphorylation of insulin receptor substrate-1 (IRS-1) that disrupts the recruitment and activation of PI3K [12], [19]. Several studies showed increased mTORC1 activity with elevated S6K1 activity in insulin-target tissues (adipose
Effects of mTOR inhibitors on glycemia
The perturbation in glucose homeostasis with mTOR inhibitors is a major metabolic complication for this class of drugs.
Pathophysiology of hyperglycemia induced by mTOR inhibitors
The role of mTOR pathway and its manipulation with mTOR inhibitors is undoubtedly complex. Notably, there are some still unexplained discrepancies between both in vitro and in vivo preclinical studies in rodents and clinical data from phase II/III studies with everolimus in humans.
It seems that mTOR inhibitors exert a “Janus effect” on glucose metabolism. Indeed, based on the observation that chronic activation of mTORC1 promotes insulin resistance, it could be hypothesized that the chronic
Management of hyperglycemia induced by mTOR inhibitors
Due to the significant effect of mTOR inhibitors on glucose metabolism, a specific management of mTOR-induced hyperglycemia has been proposed by a Task Force of the US National Cancer Institute Investigational Drug Steering Committee [53] and a French expert committee [54].
It is recommended to perform baseline measurement of fasting plasma glucose (FPG) and HbA1c before initiating a treatment with an mTOR inhibitor in order to diagnose potential pre-existing glucose metabolism disorders
Conflict of interest statement
The authors declare that there is no conflict of interest related to this review article.
Acknowledgement
This work did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
References (54)
- et al.
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
Lancet
(2008) - et al.
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
Lancet
(2013) - et al.
Defining the role of mTOR in cancer
Cancer Cell
(2007) - et al.
mTOR signaling in growth control and disease
Cell
(2012) - et al.
Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1
Cell Metab
(2006) - et al.
Insulin regulation of protein translation repressor 4E-BP1, an eIF4E-binding protein, in renal epithelial cells
Kidney Int
(2001) - et al.
ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy
J Biol Chem
(2009) - et al.
Amino acids activate mammalian target of rapamycin complex 2 (mTORC2) via PI3K/Akt signaling
J Biol Chem
(2011) - et al.
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
Mol Cell
(2006) - et al.
Insulin resistance due to phosphorylation of insulin receptor substrate-1 at serine 302
J Biol Chem
(2004)
Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in beta-cells
J Biol Chem
Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy
Cell Metab
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
Lancet
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
Lancet Oncol
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
Lancet Oncol
Metabolic complications with the use of mTOR inhibitors for cancer therapy
Cancer Treat Rev
Duration of rapamycin treatment has differential effects on metabolism in mice
Cell Metab
An emerging role of mTOR in lipid biosynthesis
Curr Biol
Acute mTOR inhibition induces insulin resistance and alters substrate utilization in vivo
Mol Metab
Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c
Cell Metab
mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc
Cell Metab
mTOR inhibition with rapamycin causes impaired insulin signalling and glucose uptake in human subcutaneous and omental adipocytes
Mol Cell Endocrinol
Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: expert proposals
Bull Cancer (Paris)
Mechanistic target of rapamycin inhibitors in solid organ transplantation: from benchside to clinical use
Curr Opin Organ Transplant
Everolimus for advanced pancreatic neuroendocrine tumors
N Engl J Med
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
N Engl J Med
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
N Engl J Med
Cited by (90)
The role of glycerol–water mixtures in the stability of FKBP12-rapalog-FRB complexes
2023, Journal of Molecular Graphics and ModellingAutophagy-nutrient sensing pathways in diabetic complications
2022, Pharmacological ResearchCitation Excerpt :Rapamycin was the first discovered mTOR inhibitor. Other anticancer mTOR inhibitors such as sirolimus, everolimus may increase the risk of new-onset of diabetes, this effect is due to an augmented insulin resistance, reduced insulin signalling pathway as well as reduced insulin secretion through pancreatic beta cells direct effect [167–169]. Role of Sirolimus was evaluated in diabetic nephropathy in rats for its effect on proteinuria.
Geroscience—the concept
2022, Anti-Aging PharmacologyMetabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper
2022, Critical Reviews in Oncology/HematologyRapamycin protects mouse skin from ultraviolet B-induced photodamage by modulating Hspb2-mediated autophagy and apoptosis
2024, Molecular Biology Reports